Arcus Biosciences, Inc.
RCUSNYSEHealthcare● Active
$23.32
+$0.13(+0.56%)
Market Cap$2.3B
P/E Ratio—
52W High$28.72
52W Low$7.91
Arcus Biosciences, Inc. (RCUS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RCUS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.25B | $0.26B | $0.12B | $0.11B | $0.38B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.24B | $0.26B | $0.12B | $0.11B | $0.38B |
| Gross Margin %(computed) | 95.95% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.52B | $0.45B | $0.34B | $0.29B | $0.26B |
| G&A Expenses | $0.11B | $0.12B | $0.12B | $0.10B | $0.07B |
| Total Operating Expenses | $0.62B | $0.59B | $0.46B | $0.39B | $0.33B |
| Operating Income | ($0.39B) | ($0.33B) | ($0.34B) | ($0.28B) | $0.05B |
| Operating Margin %(computed) | -156.28% | -127.91% | -290.60% | -250.00% | 14.10% |
| Interest Income | $0.00B | $0.05B | $0.04B | $0.02B | $0.00B |
| Interest Expense | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.35B) | ($0.28B) | ($0.30B) | ($0.27B) | $0.06B |
| Income Tax Expense | $0.00B | $0.00B | $0.01B | $0.00B | $0.00B |
| Net Income | ($0.35B) | ($0.28B) | ($0.31B) | ($0.27B) | $0.05B |
| Net Margin %(computed) | -142.91% | -109.69% | -262.39% | -238.39% | 13.84% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.76 |
| Wtd Avg Shares | 0.11B | 0.09B | 0.07B | 0.07B | 0.07B |
| EBITDA | ($0.34B) | ($0.27B) | ($0.29B) | ($0.26B) | $0.06B |
| EBITDA Margin %(computed) | -135.63% | -104.26% | -248.72% | -230.36% | 15.40% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Arcus Biosciences, Inc. data
About Arcus Biosciences, Inc. (RCUS) Income Statement
Arcus Biosciences, Inc. (RCUS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RCUS reported revenue of $0.25B, gross profit of $0.24B (gross margin 95.95%), and net income of ($0.35B) — a net profit margin of -142.91%.
Frequently asked questions
RCUS · 4 questionsArcus Biosciences, Inc. (RCUS) reported revenue of $0.25B for 2025, down 4.3% year-over-year.
RCUS revenueRCUS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08